Specifically, mutations in the interferon receptor and JAK1 or JAK2 kinases were observed in 2 of 4 patients, whereas a loss-of-function (LOF) mutation in B2M was observed in one patient.3 Loss of JAK1/2 in lung cancer was also shown to be associated with cases of acquired resistance.4 Here, JAK1 is linked to lung carcinoma.